Abrezekimab

CAS No. 2043952-59-4

Abrezekimab( —— )

Catalog No. M36767 CAS No. 2043952-59-4

Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 439 Get Quote
5MG 717 Get Quote
10MG 1121 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Abrezekimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13.
  • Description
    Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2043952-59-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Burgess G, et, al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018 Sep;35:67-75.?
molnova catalog
related products
  • Secukinumab B

    Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

  • Bornyl acetate

    Bornyl acetate is the main volatile constituent in numerous conifer oils and some Chinese traditional herbs.

  • Guselkumab

    Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit.